David Kramer: The first US production in 30 years of molybdenum-99, the parent isotope of the most widely used medical radioisotope, is expected to begin within weeks after federal regulators approved a manufacturing process developed by Wisconsin-based NorthStar Medical Radioisotopes. NorthStar received $25 million in matching funds from DOE for development of the neutron capture process and $14.8 million of an expected $25 million total for its accelerator approach.
